Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2015

Open Access 01-12-2015 | Erratum

Erratum to: Mechanistic attributes of S100A7 (psoriasin) in resistance of anoikis resulting tumor progression in squamous cell carcinoma of the oral cavity

Authors: Kaushik Kumar Dey, Siddik Sarkar, Ipsita Pal, Subhasis Das, Goutam Dey, Rashmi Bharti, Payel Banik, Jay Gopal Ray, Sukumar Maity, Indranil kulavi, Mahitosh Mandal

Published in: Cancer Cell International | Issue 1/2015

Login to get access

Excerpt

Unfortunately, the original version of this article contained an error. The name of one author Jay Gopal Ray was included incorrectly. The correct name can be found below: …
Metadata
Title
Erratum to: Mechanistic attributes of S100A7 (psoriasin) in resistance of anoikis resulting tumor progression in squamous cell carcinoma of the oral cavity
Authors
Kaushik Kumar Dey
Siddik Sarkar
Ipsita Pal
Subhasis Das
Goutam Dey
Rashmi Bharti
Payel Banik
Jay Gopal Ray
Sukumar Maity
Indranil kulavi
Mahitosh Mandal
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2015
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-015-0244-7

Other articles of this Issue 1/2015

Cancer Cell International 1/2015 Go to the issue

Primary research

Changes in DNA methylation are associated with the development of drug resistance in cervical cancer cells

Primary research

Chemosensitizing and nephroprotective effect of resveratrol in cisplatin –treated animals

Review

Potential targets for ovarian clear cell carcinoma: a review of updates and future perspectives

Primary research

Analysis of the expression of PHTF1 and related genes in acute lymphoblastic leukemia

Primary research

Treatment with the PARP inhibitor, niraparib, sensitizes colorectal cancer cell lines to irinotecan regardless of MSI/MSS status

Primary research

Expression of long non-coding RNA DLX6-AS1 in lung adenocarcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits